<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871596</url>
  </required_header>
  <id_info>
    <org_study_id>16-PHX-0003</org_study_id>
    <nct_id>NCT02871596</nct_id>
  </id_info>
  <brief_title>Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds</brief_title>
  <official_title>Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds - a Randomized, Placebo-controlled, Double-blind, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmanex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Utah State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmanex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effects of both an anthocyanin-rich polyphenol&#xD;
      blend and an anthocyanin-rich polyphenol blend combined with a prebiotic blend on fecal&#xD;
      microbiota metabolism (assessed by gas chromatograph - mass spectrometry (GC-MS) headspace&#xD;
      analysis) and fecal microbiota composition (assessed by next generation sequencing).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fecal volatile methyl sulfides at day 21, day 63, day 105</measure>
    <time_frame>baseline, day 21, day 63, day 105</time_frame>
    <description>assessed by gas chromatograph - mass spectrometry (GC-MS) headspace analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in all fecal VOCs at day 21, day 63, day 105</measure>
    <time_frame>baseline, day 21, day 63, day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline fecal short chain fatty acids at day 21, day 63, day 105</measure>
    <time_frame>baseline, day 21, day 63, day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline fecal microbiota composition at day 21, day 63, day 105</measure>
    <time_frame>baseline, day 21, day 63, day 105</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo,Flavonoids,Flavonoids+Prebiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo,Flavonoids+Prebiotics,Flavonoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavonoids,Placebo,Flavonoids+Prebiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavonoids,Flavonoids+Prebiotics,Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavonoids+Prebiotics,Placebo,Flavonoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavonoids+Prebiotics,Flavonoids,Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A combination of maltodextrins and red and blue food colors.</description>
    <arm_group_label>Flavonoids+Prebiotics,Flavonoids,Placebo</arm_group_label>
    <arm_group_label>Flavonoids+Prebiotics,Placebo,Flavonoids</arm_group_label>
    <arm_group_label>Flavonoids,Flavonoids+Prebiotics,Placebo</arm_group_label>
    <arm_group_label>Flavonoids,Placebo,Flavonoids+Prebiotics</arm_group_label>
    <arm_group_label>Placebo,Flavonoids+Prebiotics,Flavonoids</arm_group_label>
    <arm_group_label>Placebo,Flavonoids,Flavonoids+Prebiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavonoids</intervention_name>
    <description>A combination of blueberry extract, black current extract, and black rice extract.</description>
    <arm_group_label>Flavonoids+Prebiotics,Flavonoids,Placebo</arm_group_label>
    <arm_group_label>Flavonoids+Prebiotics,Placebo,Flavonoids</arm_group_label>
    <arm_group_label>Flavonoids,Flavonoids+Prebiotics,Placebo</arm_group_label>
    <arm_group_label>Flavonoids,Placebo,Flavonoids+Prebiotics</arm_group_label>
    <arm_group_label>Placebo,Flavonoids+Prebiotics,Flavonoids</arm_group_label>
    <arm_group_label>Placebo,Flavonoids,Flavonoids+Prebiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavonoids+Prebiotics</intervention_name>
    <description>A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.</description>
    <arm_group_label>Flavonoids+Prebiotics,Flavonoids,Placebo</arm_group_label>
    <arm_group_label>Flavonoids+Prebiotics,Placebo,Flavonoids</arm_group_label>
    <arm_group_label>Flavonoids,Flavonoids+Prebiotics,Placebo</arm_group_label>
    <arm_group_label>Flavonoids,Placebo,Flavonoids+Prebiotics</arm_group_label>
    <arm_group_label>Placebo,Flavonoids+Prebiotics,Flavonoids</arm_group_label>
    <arm_group_label>Placebo,Flavonoids,Flavonoids+Prebiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of any race or ethnicity between 18 to 70 years of age, inclusive;&#xD;
&#xD;
          -  Body mass index (BMI) between 20 - 32 inclusive;&#xD;
&#xD;
          -  Non-smoking status;&#xD;
&#xD;
          -  Willing to consume assigned dietary supplements for a total of 6 weeks;&#xD;
&#xD;
          -  Have access to email and a digital camera or camera phone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 or &gt;70 years;&#xD;
&#xD;
          -  BMI &lt;20 or &gt;32;&#xD;
&#xD;
          -  Uncontrolled hypertension defined as diastolic blood pressure ≥95 mm Hg or systolic&#xD;
             blood pressure ≥160 mm Hg;&#xD;
&#xD;
          -  Self-reported presence of atherosclerotic disease and/or cardiopulmonary disease;&#xD;
&#xD;
          -  Renal, hepatic, endocrine, gastrointestinal or other systemic disease;&#xD;
&#xD;
          -  For women, pregnancy, breast feeding or postpartum less than 6 months;&#xD;
&#xD;
          -  Current participation in another research study;&#xD;
&#xD;
          -  Allergy to the components in the dietary supplement (inulin, fructooligosaccharide,&#xD;
             blueberries, black currant, rice);&#xD;
&#xD;
          -  History of drug or alcohol abuse;&#xD;
&#xD;
          -  Use of antibiotics within the last 6 months;&#xD;
&#xD;
          -  Use of prebiotics or flavonoid-containing dietary supplements within the last 30 days;&#xD;
&#xD;
          -  Multiple food allergies or significant food preferences or restrictions that would&#xD;
             interfere with diet adherence;&#xD;
&#xD;
          -  Chronic use of over-the-counter medication which would interfere with study endpoints&#xD;
             including NSAIDS, laxatives and antacids;&#xD;
&#xD;
          -  Participating in or planning to begin a weight loss diet during the study period;&#xD;
&#xD;
          -  Lifestyle or schedule incompatible with the study protocol;&#xD;
&#xD;
          -  Other medical, psychiatric, or behavioral conditions that in the view of the principal&#xD;
             investigator may present a safety hazard to the participant or interfere with study&#xD;
             participation or the ability to follow the intervention protocol;&#xD;
&#xD;
          -  Use of tobacco products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lefevre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Utah State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Utah State University</name>
      <address>
        <city>Logan</city>
        <state>Utah</state>
        <zip>84322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

